US Patent Issued to ALTRARTIS THERAPEUTICS on Aug. 18 for "Formulations of psilocybin and psilocin compounds as serotonin agonists in combination with 3,4 methylenedioxymethamphetamine (MDMA)" (Colorado Inventor)

ALEXANDRIA, Va., Aug. 18 -- United States Patent no. 12,708,635, issued on Aug. 18, was assigned to ALTRARTIS THERAPEUTICS INC. (New York).

"Formulations of psilocybin and psilocin compounds as serotonin agonists in combination with 3,4 methylenedioxymethamphetamine (MDMA)" was invented by Robert Fletcher Roscow (Longmont, Colo.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention is directed to the use of psilocybin and/or psilocin compounds in combination with 3,4-methylenedioxymethamphetamine (MDMA) or other entactogens, to modulate activity of serotonin receptors, and preferably the 5-HT2A serotonin receptor in humans. In certain preferred embodiment, the co-formulation of psilocybin and/...